ARCA biopharma Enters Material Definitive Agreement
Ticker: ORKA · Form: 8-K · Filed: Jul 9, 2024 · CIK: 907654
| Field | Detail |
|---|---|
| Company | Arca Biopharma, Inc. (ORKA) |
| Form Type | 8-K |
| Filed Date | Jul 9, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-definitive-agreement
TL;DR
ARCA bio just signed a big deal, filing shows.
AI Summary
On July 3, 2024, ARCA biopharma, Inc. entered into a material definitive agreement. The company, previously known as NUVELO INC and HYSEQ INC, is incorporated in Delaware and headquartered in Westminster, Colorado.
Why It Matters
This filing indicates a significant new contract or partnership for ARCA biopharma, which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — Entering into a material definitive agreement can carry significant risks related to the terms, obligations, and potential outcomes of the agreement.
Key Players & Entities
- ARCA biopharma, Inc. (company) — Registrant
- NUVELO INC (company) — Former company name
- HYSEQ INC (company) — Former company name
- July 3, 2024 (date) — Date of earliest event reported
FAQ
What is the nature of the material definitive agreement entered into by ARCA biopharma, Inc.?
The filing states that ARCA biopharma, Inc. entered into a material definitive agreement on July 3, 2024, but the specific details of the agreement are not provided in this excerpt.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on July 3, 2024.
What are the former names of ARCA biopharma, Inc.?
ARCA biopharma, Inc. was formerly known as NUVELO INC and HYSEQ INC.
In which state is ARCA biopharma, Inc. incorporated?
ARCA biopharma, Inc. is incorporated in Delaware.
What is the business address of ARCA biopharma, Inc.?
The business address of ARCA biopharma, Inc. is 10170 Church Ranch Way, Suite 100, Westminster, Colorado 80021.
Filing Stats: 743 words · 3 min read · ~2 pages · Grade level 13 · Accepted 2024-07-09 17:01:28
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value ABIO The Nasdaq Capital M
Filing Documents
- ea0209134-8k425_arcabio.htm (8-K) — 33KB
- ea020913401ex10-1_arcabio.htm (EX-10.1) — 11KB
- ea020913401ex10-2_arcabio.htm (EX-10.2) — 145KB
- 0001213900-24-060156.txt ( ) — 399KB
- abio-20240703.xsd (EX-101.SCH) — 3KB
- abio-20240703_lab.xml (EX-101.LAB) — 33KB
- abio-20240703_pre.xml (EX-101.PRE) — 22KB
- ea0209134-8k425_arcabio_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ARCA biopharma, Inc. (Registrant) Date: July 9, 2024 By: /s/ C. Jeffrey Dekker Name: C. Jeffrey Dekker Title: Chief Financial Officer 2